Exploring Gut Microbiota in Systemic Lupus Erythematosus: Insights and Biomarker Discovery Potential

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by chronic inflammation and multi-organ damage, influenced by genetic, environmental, and immunological factors. Recent research highlights the significant role of gut microbiota in the pathogenesis and progression of SLE, suggesting that dysbiosis-an imbalance in the microbial community-can contribute to disease onset and severity. The gut microbiota, through its metabolites, interacts with the host's immune system, influencing immune responses and maintaining intestinal barrier integrity. These interactions have positioned the gut microbiota as a potential source of diagnostic biomarkers and therapeutic targets for SLE. This review delves into the mechanisms by which gut microbiota influences SLE, exploring how alterations in microbial composition and function can trigger autoimmune responses. We also examine the potential of gut microbiota-derived metabolites as biomarkers for early diagnosis and disease progression monitoring. Additionally, the therapeutic implications of modulating gut microbiota through dietary interventions, probiotics, prebiotics, and other microbiota-targeted therapies are discussed as promising strategies for managing SLE. The findings suggest that a deeper understanding of the gut microbiota's role in SLE could lead to more personalized and effective treatments, potentially transforming the approach to managing this chronic autoimmune condition. Future research should focus on elucidating the precise mechanisms of gut microbiota interaction with the immune system and its impact on SLE, as well as validating gut microbiota-based biomarkers and therapies in clinical settings.